Significant benefits were reported in steroid-free quiescence, retinal vascular leakage, macular edema, and visual functioning No new safety signals were identified, and Priovant plans an FDA ...

LUCIA did not achieve the primary endpoint of statistical noninferiority in mean change in BCVA versus on-label aflibercept (Eylea, Regeneron) control, despite demonstrating visual improvement. Key ...

The FDA has approved Genentech’s Enspryng (satralizumab-mwge) for the treatment of adults with thyroid eye disease (TED), making it the first and only subcutaneous treatment for the condition that can ...

Eclipse Life Sciences announced positive topline results from its phase 2 BETTIS-1 clinical trial evaluating EC-104, a biodegradable intravitreal fluocinolone acetonide implant, for the treatment of ...

Get breaking ophthalmic news, device and drug updates, clinical trial coverage, thought-leader perspective, and industry announcements.

Cosmetic and personal care products were associated with an estimated 42,457 emergency department visits for ocular injuries from 2005 to 2024 Young children faced disproportionate risks from chemical ...

Get breaking ophthalmic news, device and drug updates, clinical trial coverage, thought-leader perspective, and industry announcements.

Get breaking ophthalmic news, device and drug updates, clinical trial coverage, thought-leader perspective, and industry announcements.

Get breaking ophthalmic news, device and drug updates, clinical trial coverage, thought-leader perspective, and industry announcements.

Key Takeaways SYNCHRONICITY met both co-primary endpoints at 6 months, with improvements in BCVA and CST maintained through ...

Key Takeaways STK-002 is an investigational RNA-based therapy designed to increase OPA1 protein expression in patients with autosomal dominan ...

Get breaking ophthalmic news, device and drug updates, clinical trial coverage, thought-leader perspective, and industry announcements.